Source: MediCapture, Inc.

LONDON, June 29, 2018 /PRNewswire/ —

SSRN, Elsevier’s world leading preprint server and early stage research platform, has today announced the launch of ‘Preprints with The Lancet‘ – a new preprint series for sharing early stage health and medical research.

The collaboration brings together SSRN with The Lancet as part of a six-month pilot to assess whether the health and medical community are ready for this form of early research sharing.

Preprints are research papers that are at the submission stage or can be described as on-going research. By sharing online, authors widen the opportunity for receiving comments on their work by other researchers with the goal of an improved final peer-reviewed publication and for exchange of research areas with the future potential for collaboration. Preprints are primarily intended for research use; they have not been through the important steps of peer review and experienced editorial scrutiny and guidance that is part of the publishing process. All papers on ‘Preprints with The Lancet‘ will be free to upload and download.

Dr. Richard Horton, Editor-In-Chief of The Lancet, said: “Preprints have a long history in physics, mathematics, and, more recently, social sciences and biological fields, but medicine and health have been lagging behind. Our preprint pilot will be a first attempt to establish whether there is an appetite in the medical research community for obtaining feedback on ongoing or submitted research in the form of preprints, and whether such postings are a useful step in the research and publishing process.”

Authors of all research papers submitted to any Lancet family journal, will be asked at submission whether they would like their paper to be posted – as a preprint, an opt-in that all co-authors must agree to. Authors can also submit their papers through SSRN directly.

Submitted papers will be subject to SSRN’s usual checks to ensure that the paper is part of the scholarly discourse, in a subject area covered by one or more of SSRN’s networks. A Lancet editor will then check the paper and ensure the authors have provided a statement about the funding of the study; a summarized declaration of interests for all authors; a statement on ethics approval or why the research was exempted; and if the research is a randomized trial, confirmation that it has been prospectively registered along with the trial registration number. Once a final version of a preprint paper is peer-reviewed and published and becomes part of the scientific evidence as the version of record, authors are encouraged to link to the preprint of the published paper.

Gregg Gordon, Managing Director of SSRN, added: “It’s fantastic The Lancet has decided to embrace preprints and launch this new series. We have over 20 years’ experience helping researchers from across the world, and from all scientific disciplines, collaborate and share their early stage research. With the new Sneak Peek series from Cell Press recently launched on SSRN, we have two of the world’s leading journals from Elsevier working in partnership with us.”

Note for editors 

Interviews with Gregg Gordon, Managing Director of SSRN, are available on request.

For more information about Preprints with The Lancet please see: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31125-5/fulltext and https://www.thelancet.com/preprints.

About SSRN 

SSRN is a worldwide collaborative of over 350,000 authors and more than 2.2 million users that is devoted to the rapid worldwide dissemination of research. Founded in 1994, it is now composed of a number of specialized research networks. Each of SSRN’s networks encourages the early distribution of research results by reviewing and distributing submitted abstracts and full text papers from scholars around the world. SSRN encourages readers to communicate directly with other subscribers and authors concerning their own and other’s research. Through email abstract eJournals, SSRN currently reaches over 400,000 people in approximately 140 different countries.

About Elsevier 

Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 38,000 e-book titles and many iconic reference works, including Gray‘s Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. http://www.elsevier.com

Media contact 
David Tucker, Global Communications
Elsevier
+44-7920-536-160
d.tucker@elsevier.com

NEW YORK, June 27, 2018 /PRNewswire/ — It was announced on June 15 EST in a 8-K notice from SEC that China Golden Sunset Group Limited (“CGSGL”) was finally listed in the US stock market through reverse takeover of DD’s Deluxe Rod Holder, Inc. (stock code: DDLX). CGSGL thus becomes the first company listed in the US capital market in the elderly care industry and will be supported by the international capital. Extensive attention from the industry has been attracted by CGSGL’s surprising growth speed. 

The successful entry into US OTC markets of GSGL acting as the first China’s concept stock of elderly care means that it will have an absolute advantage against any other competitor in the future market occupancy. Therefore, it is a strategic selection for CGSGL to exploit the international market. With the support of international capital , CGSGL is full of confidence to expand GSGL into one of the global top 500 companies in the elderly care industry in the coming future and in answer to China’s economic development trend. GSGL will be a leader in the elderly care industry in China.

12- year experience and efforts

CGSGL began with operating Xiyanghong Ecological Elderly Apartments and continued its commitment to the elderly care industry for 12 years, making an indelible contribution to the industry. In order to inherit and carry forward the Chinese traditional virtues of “filial piety makes virtue possible “, it has entered into the cooperative agreements of entrusted operation with scores of domestic nursing institutions for the aged so as to improve the living quality of the aged in all aspects and offer dignified lives for the aged.

Ms. Quan Jun, chairman of the board of CGSGL, said today in interview with a reporter of ICN, ” We are mainly engaged in collective nursing of the aged, so we set up a service system combining the nursing by professional institutions, the nursing through residing abroad and the nursing by communities. The group has integrated many resources including medical rehabilitation, health maintenance, entertainment, etc. to provide high quality and professional elder care services for the aged. In the future, we will set up a close cooperative relation with the nursing institutions for the aged across the country offering them a professional service system, and exploit overseas markets. Nowadays, the group has been listed in the US, which demonstrates its keeping ahead in the elderly care industry and also contributes to our copying the past success in the world.”

Epoch-making strategy to create surprise

2018 is a milestone for CGSGL. Besides being listed in the US, the group actively cooperates with other institutions in developing the markets of the nursing by professional institutions, the nursing through residing abroad and the nursing by communities. The nursing by communities is advocated by governments; the nursing by communities provided by CGSGL is endowed with culture, spirit, family affection and health on the basis of the traditional nursing, thus being popular among the aged and attracting the attention from the whole country including governments. The nursing through residing abroad is increasingly a trend; CGSGL took a over-two-year effort to create 12 travel routes for the aged in the country. “Mutual promotion between the nursing and the undertaking (industry) ” is the strategy for the stable advance of the group all the times.  

Aging of population is a challenge and also an opportunity. The aged are not a burden but the resource of the society. Active respondance to aging means removal of the negative image of the aged such as recession, degeneration and loss; the aged may contribute to the society and achieve self-worth through mutual support. The concept of “Positive Aging” defined by W.H.O will be constructed or explained by health, guarantee and participation.

Sticking to the advanced development thinking and accelerating the elderly care industry, CGSGL is committed to the elder care services. CGSGL promotes the progress of policies, standards, facilities and talents for the aged nursing industry, and endeavors to set up an aged nursing service system which is based on the home, supported by the communities and supplemented by the external institutions with the combination of the nursing and the medical care, for the purpose of further satisfying the requirements of the aged.

Photo – https://photos.prnasia.com/prnh/20180627/2174592-1

MENLO PARK, California and SOUTH PLAINFIELD, New Jersey, June 27, 2018 /PRNewswire/ — Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leading provider of high-quality sequencing systems for genomes, transcriptomes and epigenomes, and GENEWIZ, a leading global genomics service provider, today announced that Professor Dr. Arne Nolte of the Institute for Biology and Environmental Sciences at the University of Oldenburg, Germany and Assistant Professor Dr. Fritz Sedlazeck from the Human Genome Sequencing Center at Baylor College of Medicine in Houston, have been awarded the 2018 Plant and Animal SMRT® Grant. The grant will provide Nolte and Sedlazeck access to the PacBio® Sequel® System at GENEWIZ, as well as the materials needed and bioinformatics support to conduct comparative genomics on the newly discovered European cavefish. 

The fish, Cave barbatula, was discovered in 2015 by diver Joachim Kreiselmaier as he explored the deepest parts of the Danube-Aach cave system in Southern Germany. After discussing this “strange fish” with friend and ecologist Assistant Professor Dr. Jasminca Behrmann-Godel of the Limnological Institute of the University of Konstanz, Kreiselmaier brought back a live sample for analysis.

Cavefish are found in hostile subterranean environments that lack light and nutrition and have evolved to live in a world of darkness. The fish Kreiselmaier found showed typical adaptions to cave life such as a pale body coloration, much smaller eyes, and larger nares and barbels when compared to loaches from surface locations nearby. It represents the first cavefish discovery in Europe, as well as the northernmost in the world.

Nolte and Sedlazeck have joined efforts with Behrmann-Godel to further understand the evolution of the European cavefish from its ancestors in surface waters and among other cave species, and a high-quality genome assembly will allow them to investigate the genetic make-up of organisms, including all features that are essential to understand gene function. This allows for the comparison among species to infer evolutionary changes at the level of the genome. Single Molecule, Real-Time (SMRT) Sequencing on the Sequel System provides long read lengths with uniform coverage, which leads to high accuracy and contiguity, both essential to generate complete and accurate views of a genome.

According to Dr. Fritz Sedlazeck, Assistant Professor at Baylor College of Medicine:
“This grant enables us to establish the genome assembly of the European cavefish and identify genetic variants from its surface-water ancestors. We are fascinated by changes in the sensory system and pale pigmentation of the fish and we will compare its genomic makeup with the Mexican cavefish which is an important model organism in developmental biology. The outcome of this study will enable us to understand the initial steps that lead to the evolution of cave animals and impact our understanding of how multiple phenotypes evolve among vertebrates.”

According to Kevin Corcoran, Senior Vice President of Market Development for Pacific Biosciences:
“We are pleased once again to partner with our certified service provider GENEWIZ to bring the winners of the 2018 Plant and Animal SMRT Grant access to highly accurate, long-read sequencing that will help further their understanding of the evolution of the European cavefish.”

According to Dr. Ginger Zhou, Vice President, Global Next Generation Sequencing for GENEWIZ:
“The combination of PacBio’s powerful genomics platforms and GENEWIZ’s depth of experience in genomics and next generation sequencing provides researchers like Drs. Nolte and Sedlazeck the technology and support they require to further their discoveries and understanding of the world around us.”

For more information about whole genome sequencing on the Sequel System, visit: https://www.pacb.com/applications/whole-genome-sequencing/

For more information on whole genome sequencing with GENEWIZ, including long-read sequencing on the Sequel System, visit: https://www.genewiz.com/ngs

Photo credit: ©Jasminca Behrmann-Godel

ABOUT GENEWIZ
GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in Sanger sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory-compliant services.

Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a network of laboratories in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, Suzhou, Tianjin, and Guangzhou, China; Takeley, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat, and Weibo.

ABOUT PACIFIC BIOSCIENCES
Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

FORWARD-LOOKING STATEMENTS
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the suitability or utility of methods or products for particular applications, future availability, uses, quality or performance of, or benefits of using, products or technologies, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

LOS ANGELES, June 26, 2018 /PRNewswire/ — ANCHEER understands advanced technology heralds new technologies to be used for humanity’s progress. A developing technology is artificial intelligence (AI), one that allows computer systems to perform tasks that humans normally do. Some of which include language translation, speech recognition, visual perception, and even decision making.

AI allows a program to do something that would normally require human intelligence. It offers great advantages in a number of things. Ranging from dealing with mundane tasks to machines taking the risk in place of humans, there could be massive potential for AI if utilized properly.

Utilizing that potential, a future development using AI technology is on the works. Since last year, the use of AI in bicycles has been teased by several manufacturers. This year, ANCHEER is pushing the development of these new AI-powered bicycles. ANCHEER is launching a new product proposal aimed to produce health bikes using AI technology to help health and fitness enthusiasts.

For decades, ANCHEER has provided premium-quality products to their customers, and now they take another step forward by using artificial intelligence to power and operate their electric bikes. More than that, this particular technology will allow bikers to use their data and turn it into insights. For people who are keen about their health, the insights provided by AI-powered bikes are vital.

These insights can help them to optimize users’ routing and health. Users can use the organized data obtained by AI bikes to create a better riding plan to improve their health and fitness. ALCHEER’s proposed new product will make use of the information to make efficient use of the bikes.

In addition, the AI-powered bikes will be able to use huge amounts of data available within the city. This information is difficult to understand and organize, which AI will be able to structure to apply for a wide array of uses. One of those uses is scheme efficiency, providing users with real-time intelligence for predicting and optimizing the users’ route throughout the city.

Other than the bikes, ANCHEER is also aiming to expand the use of artificial intelligence to their skateboard brand. If product development ensues, even skateboard users can take advantage of the benefits that artificial intelligence provides.

In healthcare, users of ANCHEER’s AI skateboards and bikes can use specific algorithms built-in within the product to analyze and understand complex medical data. It will make it easier to analyze prevention or treatment techniques as well as patient outcomes. With their new product, ANCHEER strongly believes that AI will lead the future of healthcare.

About The Company:

ANCHEER is a Los Angeles-based premium distributor of first-rate health and fitness products. It has established professional relationships allowing them to provide to customers more competitive pricing for the highest-quality product compared to average distributors. Excellent customer service and premium products are what makes ANCHEER one of the leaders in the industry.

For more information, please visit https://www.ancheer.shop or email service.ancheer@gmail.com.

View original content:http://www.prnewswire.com/news-releases/ancheer-leads-development-of-bicycles-utilizing-ai-technology-as-part-of-its-product-expansion-300671392.html

– Starpharma licenses VivaGel^® BV to Mundipharma for Europe, Russia, CIS¹ and the balance of Latin America to be marketed as part of the popular BETADINE^® Feminine Care portfolio

– Deal terms include a financially attractive revenue share, plus an upfront fee and eligible milestones which total up to US$15.5M

– This deal brings the total eligible milestones payable to Starpharma for all Mundipharma territories up to US$24.7M, plus revenue share

– Mundipharma plans to launch VivaGel^® BV in Europe as soon as practicable

SINGAPORE, June 27, 2018 /PRNewswire/ — Starpharma (ASX: SPL, OTCQX: SPHRY) and Mundipharma today announced they have signed a licence agreement for the sales and marketing rights to VivaGel^® BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America. This deal builds on the VivaGel^® BV licence signed with Mundipharma in May 2018 for Asia, the Middle East, Africa and parts of Latin America.

Mundipharma is a leading global pharmaceutical company and owns the successful international brand – BETADINE^®. It is one of the largest privately-owned pharmaceutical companies in the world employing over 8,600 people.

The European region is an important addition to the territories already under licence with Mundipharma. Europe represents a large commercial opportunity for VivaGel^® BV, enabling access to more than 260 million women. Coupled with the European Union (EU) regulatory approval already in place, this licence is expected to provide a rapid timeline for product launch. Mundipharma will proceed to launch the product under its BETADINE^® brand as soon as practicable with first launches targeted for early 2019.

Consistent with the previous Mundipharma deal, Starpharma will receive returns via a revenue share on VivaGel^® BV sales and is also eligible to receive signing, launch and other commercial milestones. Under the European deal, eligible milestones total up to A$20.9 million (US$15.5 million), including a US$1.5 million upfront payment. The combination of territories now under licence with Mundipharma means Starpharma is eligible to receive total signing, regulatory and commercial milestones of up to US$24.7 million, in addition to receiving revenue share.

The term of this licence is 15 years and contains commercial performance obligations, including minimum annual purchases by Mundipharma. Mundipharma is responsible for marketing, promotion and sales of the product in its licensed territories. Starpharma retains ownership of the VivaGel^® BV trademark and will supply Mundipharma with VivaGel^® BV. Other commercial terms of the agreement remain confidential.

Commenting on the licence, Dr Jackie Fairley, CEO of Starpharma said: “We are delighted to expand our commercial relationship with Mundipharma, owners of the rapidly growing feminine care brand, BETADINE^®. In particular, Europe represents a very important market for VivaGel^® BV and with this licence in place, VivaGel^® BV will soon be available to millions of European women who suffer from BV. We’re impressed by Mundipharma’s commitment to the feminine care category and their plans to expedite the product launch through their extensive marketing network in Europe.”

Raman Singh, Mundipharma CEO, commented: “We’re excited to be working with Starpharma in an area of significant unmet need and to be adding this highly innovative product, VivaGel^® BV, to our BETADINE^® feminine care range throughout additional regions, including Europe.”

The signing of this licence for Europe is the culmination of a competitive process undertaken by Starpharma involving multiple leading pharmaceutical and women’s health companies. Significant weighting was applied to commercial terms, each company’s marketing and sales capabilities, as well as their planned time to market.

Starpharma is also in advanced commercial negotiations for marketing rights to VivaGel^® BV in North America and expects to announce further licensing arrangements in the near future. Starpharma lodged its New Drug Application (NDA) with the US FDA under a Fast Track designation in April 2018.

About VivaGel® BV

VivaGel® BV is a patented, water-based vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV. VivaGel® BV is a breakthrough product which specifically targets the organisms that cause BV, rapidly relieves symptoms and has a novel mechanism of action affecting biofilm. VivaGel® BV is a non-antibiotic therapy and is not absorbed into the bloodstream.

About Bacterial Vaginosis (BV)

Bacterial vaginosis is the most common cause of vaginal infection for women of childbearing age and affects around 30% of women in the US. It is a highly recurrent condition with 50‑60% of sufferers having it recurrently. BV is caused by an imbalance of naturally occurring bacterial flora (the usual bacteria found in a woman’s vagina). Current therapies for BV are inadequate and have many unpleasant side-effects, there are also no approved products in the US for recurrent BV making VivaGel® BV a first-in-class therapy supported by large, randomised clinical studies.

About Mundipharma

Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organization that consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. For more information please visit: www.mundipharma.com

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma’s underlying technology is built around dendrimers — a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel^® portfolio and DEP^® drug delivery with the Company developing several products internally and others via commercial partnerships.

VivaGel^®: Starpharma’s women’s health product – VivaGel^® BV is based on SPL7013, astodrimer sodium, a proprietary dendrimer.  VivaGel^® BV is approved for marketing in the EU and Australia for bacterial vaginosis (BV) and a new drug application is under Fast Track review by the US FDA. Starpharma has licensed the sales and marketing of VivaGel^® BV to Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel^® condom (an antiviral condom which includes VivaGel^® in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel^® condom has been launched in Australia and Canada under the Lifestyles^® Dual Protect™ brand.

DEP^® – Dendrimer Enhanced Product^®: Starpharma’s DEP^® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP^® programs, including improved efficacy, safety and survival. Starpharma has two internal DEP^® products – DEP^® docetaxel and DEP^® cabazitaxel – in clinical development in patients with solid tumours, and further DEP^® products approaching clinical development. Starpharma’s partnered DEP^® programs include a multiproduct DEP^® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more.

Starpharma.com | Twitter  | LinkedIn

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”,  “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Logo – http://photos.prnasia.com/prnh/20150302/8521501264LOGO

HONG KONG, June 26, 2018 /PRNewswire/ — Ms. Kimberly Nearing, the Managing Director, Head of Life Sciences at Cedrus Investments (“Cedrus”), was invited to serve on a panel and as a judge at the Sino-American Pharmaceutical Professionals Association’s (SAPA) Pharma/Biotech Investment Summit and Roadshow held on June 16 at Columbia University in New York City.

The sold-out event featured plenary sessions about global life sciences investment environment in the morning and life science company roadshow in the afternoon. Keynote speeches were made by Aisling Capital, Lilly, BeyondSpring Pharmaceuticals, Inc., Asian Ventures, F-Prime Capital Partners, and the U.S. National Institutes of Health’s Office of Technology Transfer. A highlight of the event was a presentation delivered by Mr. Dennis Purcell, Founder and Senior Advisor at Aisling Capital and former Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist), who reflected on what has changed in the global biotech industry and the rise in China’s influence.

Ms. Nearing participated in the Business Development and Strategic Investments panel along with US Head of Global Business Development at Hengrui Medicine, Deputy General Manager, Strategic Development at Shanghai Fosun Pharmaceutical Development Co. Ltd., and Managing Director, Co-leader for China/US Cross-Border Deals at PwC. She also served as a judge on the Showcase and Roadshow session, along with the Director, Corporate Development at Merck, Senior Analyst at Citi’s Biotech Equity, and Senior Associate at OrbiMed Advisors. 

Mr. Xiaodong Chen, Chair of China Affairs at SAPA said, “On behalf the SAPA Leadership, we’d like to thank Kim for her unique insights into cross-border partnering and investing in the healthcare industry between the U.S. and China in the fireside chat session and her wisdom as a roadshow advisor. Kim made a great contribution to another successful SAPA event.”

About Cedrus Investments

Cedrus Investments is a global boutique investment firm that offers expertise in private wealth management, asset management and financial advisory services to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

TAIPEI, Taiwan, June 26, 2018 /PRNewswire/ — Recently, BioGend Therapeutics, a leading regenerative medicine company that focuses on bone and cartilage repair and regeneration, announced that BioGend Therapeutics completes enrollment for the pivotal clinical trial of one-step autologous knee cartilage repair/regeneration.

The company is led by an experienced management team in business operation, orthobiologic R/D, and clinical and regulatory affairs. The Biphasic Cartilage Repair Implant (BiCRI) technology, one of BioGend’s two major orthobiologic platforms, is a one-step autologous cartilage repair treatment for knee chondral or osteochondral defects (see Figure 1). During the surgery, a small amount of healthy cartilage tissue is harvested from the non-weight bearing area and mechanically reduced to small fragments followed by a brief enzymatic treatment to improve chondrocytes bioactivity and mobility. The cartilage tissue fragments are delivered using a bioabsorbable porous cylindrical biphasic plug to the defect site. The entire operation can be done arthroscopically in less than one hour. The pivotal clinical trial just completed enrollment of all 92 patients required to demonstrate non-inferiority at one-year follow-up. BioGend expects to receive TFDA approval in late 2019. A small cohort of 10 patients treated with the BiCRI device in a pilot study continues to demonstrate sustained good clinical performance at 5 years follow-up. The company is in the process of discussing with potential global strategic partners to develop markets in China, EU and the US for its one-step simple and effective autologous BiCRI cartilage technology.

Osteoinductive Factor (OIF) technology, another BioGend’s orthobiologic platform, has more than 10 years preclinical data demonstrating the safety and efficacy of OIF as a bone graft substitute. OIF is produced from E. coli bacteria by a BioGend’s sister company to assure consistent high quality. A pilot clinical trial to investigate the safety of OIF/TCP for open fracture management is expected to start in the 2H2018. A multicenter multinational spinal fusion pilot study of OIF/TCP is planned to begin in the 1H2020.

BioGend is preparing to list in Taipei Exchange next year to raise the fund required for launching the BiCRI product in Taiwan in early 2020. The company is also planning to bring knee cartilage patients from China and Southeaster Asia to Taiwan for surgery. BioGend welcome to discuss with potential strategic partners for global business collaboration, including investment in BioGend company.

Media contact:
Te-Li Chen
886-2-2655-8366#6300
886-922-338-294
tl.chen@biogend.com.tw